Aripiprazole for the treatment of methamphetamine dependence: A randomized, double-blind, placebo-controlled trial

Addiction

Volumn 108, Issue 4, 2013, Pages 751-761

  Coffin, Phillip Oliver ^a,b   Santos, Glenn Milo ^a,b   Das, Moupali ^a,b   Santos, Deirdre M ^a   Huffaker, Shannon ^a   Matheson, Tim ^a   Gasper, James ^a,b   Vittinghoff, Eric ^b   Colfax, Grant N ^a,b  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aripiprazole; Methamphetamine; Sexual risk behaviors

Indexed keywords

ARIPIPRAZOLE; DOPAMINE RECEPTOR STIMULATING AGENT; METHAMPHETAMINE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; COMPARATIVE STUDY; CONTROLLED STUDY; COUNSELING; DOUBLE BLIND PROCEDURE; DRUG ABUSE; FEMALE; HUMAN; MALE; MEDICATION COMPLIANCE; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; REHABILITATION; SUBSTANCE ABUSE; TREATMENT FAILURE; URINE; ARTICLE; CONTROLLED CLINICAL TRIAL;

ADULT; AMPHETAMINE-RELATED DISORDERS; COMBINED MODALITY THERAPY; COUNSELING; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; METHAMPHETAMINE; PIPERAZINES; QUINOLONES; SUBSTANCE ABUSE DETECTION; TREATMENT FAILURE;

EID: 84891400253     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12073     Document Type: Article

References (43)

1. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2012, UNODC. NewYork: United Nations Office on Drugs and Crime, 2012.
2. United States Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of national findings. In: SAMHSA, editor. Office of Applied Studies, NSDUH Series. Rockville, MD: SAMHSA, Office of Applied Studies; 2010, p. 13-28.
3. Colfax G., Santos G. M., Chu P., Vittinghoff E., Pluddemann A., Kumar S. et al. Amphetamine-group substances and HIV. Lancet 2010; 376: 458-74.
4. Semple S. J., Strathdee S. A., Zians J., Patterson T. L. Correlates of trading sex for methamphetamine in a sample of HIV-negative heterosexual methamphetamine users. J Psychoac Drugs 2011; 43: 79-88.
5. Karila L.,Weinstein A., Aubin H. J., Benyamina A., Reynaud M., Batki S. L. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol 2010; 69: 578-92.
6. Vocci F., Ling W. Medications development: successes and challenges. Pharmacol Ther 2005; 108: 94-108.
7. Gonzalez G., Oliveto A., Kosten T. R. Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother 2004; 5: 713-25.
8. Jorenby D. E., Hays J. T., Rigotti N. A., Azoulay S., Watsky E. J., Williams K. E. et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, versus placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63.
9. Gonzales D., Rennard S. I., Nides M., Oncken C., Azoulay S., Billing C. B. et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, versus sustainedrelease bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55.
10. Tonstad S., Tonnesen P., Hajek P., Williams K. E., Billing C. B., Reeves K. R. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64-71.
11. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Wong C. et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 1999; 291: 409-15.
12. Campiani G., Butini S., Trotta F., Fattorusso C., Catalanotti B., Aiello F. et al. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem 2003; 46: 3822-39.
13. Cervo L., Carnovali F., Stark J. A., Mennini T. Cocaineseeking behavior in response to drug-associated stimuli in rats: involvement of D3 and D2 dopamine receptors. Neuropsychopharmacology 2003; 28: 1150-9.
14. Gal K., Gyertyan I. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend 2006; 81: 63-70.
15. Pilla M., Perachon S., Sautel F., Garrido F., Mann A., Wermuth C. G. et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999; 400: 371-5.
16. Exner M., Clark D. Agonist and antagonist activity of low efficacy D2 dopamine receptor agonists in rats discriminating d-amphetamine from saline. Behav Pharmacol 1992; 3: 609-19.
17. Izzo E., Orsini C., Koob G. F., Pulvirenti L. A dopamine partial agonist and antagonist block amphetamine selfadministration in a progressive ratio schedule. Pharmacol Biochem Behav 2001; 68: 701-8.
18. Ranaldi R., Wang Z., Woolverton W. L. Reinforcing effects of D2 dopamine receptor agonists and partial agonists in rhesus monkeys. Drug Alcohol Depend 2001; 64: 209-17.
19. Futamura T., Akiyama S., Sugino H., Forbes A., McQuade R. D., Kikuchi T. Aripiprazole attenuates established behavioral sensitization induced by methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1115-9.
20. Reid M.S., Palamar J., Flammino J., Mahoney J.J., De La Garza R., Newton T. F. et al. A double-blind, placebocontrolled assessment of aripiprazole effects on methamphetamine craving: longitudinal and cue reactivity studies. Paper presented at the The College on Problems of Drug Dependence, 68th Annual Scientific meeting, Scottsdale, Arizona, 17-22 June 2006; abstract #644; Available at http://www.cpdd.vcu.edu/Pages/Meetings/Meetings_PDFs/ 2006abstractbook.pdf (accessed 13 December 2012).
21. De la Garza R., Reid M. S., Palamar J., Mahoney J.J., Fong T., Elkashef A. et al. A double-blind, placebo-controlled assessment of potential interactions between intravenous methamphetamine and aripiprazole: preliminary finidings. Paper presented at the College on Problems of Drug Dependence (CPDD) Conference, Orlando, FL, June 2006; abstract #591; Available at http://www.cpdd.vcu.edu/Pages/ Meetings/Meetings_PDFs/2006abstractbook.pdf (accessed 13 December 2012).
22. Lile J. A., StoopsW.W., Vansickel A. R., Glaser P. E., Hays L. R., Rush C. R. Aripiprazole attenuates the discriminativestimulus and subject-rated effects of d-amphetamine in humans. Neuropsychopharmacology 2005; 30: 2103-14.
23. Stoops W. W., Lile J. A., Glaser P. E., Rush C. R. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend 2006; 84: 206-9.
24. Sevak R. J., Vansickel A. R., Stoops W. W., Glaser P. E., Hays L. R., Rush C. R. Discriminative-stimulus, subject-rated, and physiological effects of methamphetamine in humans pretreated with aripiprazole. J Clin Psychopharmacol 2011; 31: 470-80.
25. Beresford T. P., Clapp L., Martin B., Wiberg J. L., Alfers J., Beresford H. F., Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005; 25: 363-6.
26. Brown E. S., Jeffress J., Liggin J. D., Garza M., Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005; 66: 756-60.
27. Hseih F. Y., Bloch D. A., Larsen M. D. A simple method of sample size calculation for linear and logistic regression. Stat Med 1998; 17: 1623-34.
28. First M. B., Spitzer R. L., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Non-Patient Edition (SCID-I/NP, 1/2007 Revision). NewYork: Biometrics Research Department, NewYork State Psychiatric Institute; 2007.
29. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep 2001; 50: 1-57.
30. Brief D., Bollinger A., Horton G., LoCastro J. S. Relapse Prevention Treatment for Cocaine Addiction: The RPT-C Manual. Bethesda, MD: Medication Development Division, National Institute on Drug Abuse; 1998.
31. Bangsberg D., Hecht F., Charlebois E., Chesney M., Moss A. Comparing objectives measure of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav 2001; 5: 275-81.
32. Metzger D. S., Koblin B., Turner C., Navaline H., Valenti F., Holte S. et al. Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol 2000; 152: 99-106.
33. Colfax G., Vittinghoff E., Husnik M. J., McKirnan D., Buchbinder S., Koblin B. et al. Substance use and sexual risk: a participant- and episode-level analysis among a cohort of men who have sex with men. Am J Epidemiol 2004; 159: 1002-12.
34. Cheng S. T., Chan A. C., Fung H. H. Factorial structure of a short version of the Center for Epidemiologic Studies Depression Scale. Int J Geriatr Psychiatry 2006; 21: 333-6.
35. Division of AIDS (DAIDS). Table for grading severity of adult adverse experiences for the HIV prevention trials network. Bethesda, MD: National Institute of Allergy and Infectious Diseases, Division of AIDS; 2003.
36. McCann D. J., Li S. H. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther 2012; 18: 414-8.
37. Colfax G. N., Santos G. M., Das M., Santos D. M., Matheson T., Gasper J. et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry 2011; 68: 1168-75.
38. Longo M., Wickes W., Smout M., Harrison S., Cahill S., White J. M. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction 2010; 105: 146-54.
39. Anderson A. L., Li S. H., Biswas K., McSherry F., Holmes T., Iturriaga E. et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2012; 120: 135-41.
40. Newton T. F., Reid M. S., De La Garza R., Mahoney J. J., Abad A., Condos R. et al. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetaminedependent volunteers. Int J Neuropsychopharmacol 2008; 11: 1037-45.
41. Tiihonen J., Kuoppasalmi K., Fohr J., Tuomola P., Kuikanmaki O., Vorma H. et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007; 164: 160-2.
42. Sulaiman A. H., Gill J. S., Said M. A., Zainal N. Z., Hussein H. M., Guan N. C. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. Int J Psychiatry Clin Pract 2012; Epub ahead of print 10 April.
43. Volkow N. D., Wang G. J., Fowler J. S., Tomasi D., Telang F. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci USA 2011; 108: 15037-42.